Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm(3): A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of the novel H1/IC31 vaccine, a fusion protein of...

Descripción completa

Detalles Bibliográficos
Autores principales: Reither, Klaus, Katsoulis, Lynn, Beattie, Trevor, Gardiner, Nicolene, Lenz, Nicole, Said, Khadija, Mfinanga, Elirehema, Pohl, Christian, Fielding, Katherine L., Jeffery, Hannah, Kagina, Benjamin M., Hughes, Elisabeth J., Scriba, Thomas J., Hanekom, Willem A., Hoff, Søren T., Bang, Peter, Kromann, Ingrid, Daubenberger, Claudia, Andersen, Peter, Churchyard, Gavin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260867/
https://www.ncbi.nlm.nih.gov/pubmed/25490675
http://dx.doi.org/10.1371/journal.pone.0114602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260867/
https://www.ncbi.nlm.nih.gov/pubmed/25490675
http://dx.doi.org/10.1371/journal.pone.0114602

Ejemplares similares